497 reports of this reaction
0.8% of all BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE reports
#20 most reported adverse reaction
TOOTH INJURY is the #20 most commonly reported adverse reaction for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, manufactured by Gilead Sciences, Inc.. There are 497 FDA adverse event reports linking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE to TOOTH INJURY. This represents approximately 0.8% of all 62,897 adverse event reports for this drug.
Patients taking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE who experience tooth injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TOOTH INJURY is a less commonly reported adverse event for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, but still significant enough to appear in the safety profile.
In addition to tooth injury, the following adverse reactions have been reported for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE:
The following drugs have also been linked to tooth injury in FDA adverse event reports:
TOOTH INJURY has been reported as an adverse event in 497 FDA reports for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TOOTH INJURY accounts for approximately 0.8% of all adverse event reports for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, making it a notable side effect.
If you experience tooth injury while taking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.